



## DAFTAR PUSTAKA

Ikatan Dokter Anak Indonesia. (2011). *Konsensus Infeksi Saluran Kemih pada Anak*. Jakarta: Badan Penerbit IDAI.

Haryono, Rudi. (2012). *Keperawatan Medical Bedah: Sistem Perkemihan*. Rapha Publishing: Yogyakarta.

Dipiro J.t., Wells, B.G., Dipiro C.V., Schwing hammer, T.L., (2015). *Pharmacotherapy Handbook*. Ninth Edition. Mc Graw-Hill Education, USA.

Purnomo, B. B. (2014). *Dasar-dasar urologi Edisi Ketiga*. Malang: penerbit CV Sagung seto.

National Kidney and Urologic Disease Information Clearinghouse (NKUDIC). (2012). *Urinary Tract Infection in Adult*. <http://kidney.niddk.nih.gov/kudiseases/pubs/utiadult>. Di akses tanggal 4 September 2018.

Gradwohl Steven E., (2011). *Urinary Tract Infection Guideline*, May 2011

Karjono, B. J., Susilaningsih, N., & Purnawati, R. D. (2016). *Pola Kuman pada Penderita Infeksi Saluran Kemih di RSUP Dr Kariadi Semarang*. YARSI Medical Journal, 17(2), 119-124. <http://bit.ly/2oTBpk0>. Diakses tanggal 4 September 2018.

Grabe M, Bartoletti R, Bjerklund Johansen TE, et al. *EAU guidelines on urological infections*. European Association of Urology Web site. <http://uroweb.org/guideline/urological-infections/>. Updated 2015.

International Consultation on Urogenital Infections, Naber KG, European Association of Urology, International Consultation on Urological Diseases, editors. Urogenital infections. Arnhem: European Association of Urology; 2010.

NHS choices: urinary tract infections in adults. UK National Health Service Web site. <http://www.nhs.uk/conditions/urinary-tract-infection-adults/pages/introduction.aspx>. Diakses tanggal 22 oktober, 2018.

Draft global action plan on antimicrobial resistance. Report by the WHO Secretariat. World Health Organization, Geneva, Switzerland; 2015



- Elias, J., Schoen, C., Heinze, G. et al. *Nosocomial outbreak of VIM-2 metallo- $\beta$ -lactamase-producing Pseudomonas aeruginosa associated with retrograde urography.* (<http://dx.doi.org/10.1111/j.1469-0691.2009.03146.x>) Clin Microbiol Infect. 2010; 16: 1494–1500
- Hilt, E.E., McKinley, K., Pearce, M.M. et al. *Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder.* (<http://dx.doi.org/10.1128/JCM.02876-13>) J Clin Microbiol. 2014; 52: 871–876
- Foxman, B. *Epidemiology of urinary tract infections: incidence, morbidity, and economic costs.* Am J Med. 2002; 113: 5S–13S
- Pace, W.D., Dickinson, L.M., and Staton, E.W. *Seasonal variation in diagnoses and visits to family physicians.* Ann Fam Med. 2004; 2: 411–417
- Johansen, T.E.B., Botto, H., Cek, M. et al. *Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system.* (<http://dx.doi.org/10.1016/j.ijantimicag.2011.09.009>) Int J Antimicrob Agents. 2011; 38: 64–70
- Czaja, C.A., Scholes, D., Hooton, T.M., and Stamm, W.E. *Population-based epidemiologic analysis of acute pyelonephritis.* (<http://dx.doi.org/10.1086/519268>) Clin Infect Dis. 2007; 45: 273–280
- Echols, R.M., Tosiello, R.L., Haverstock, D.C., and Tice, A.D. *Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis.* (<http://dx.doi.org/10.1086/520138>) Clin Infect Dis. 1999; 29: 113–119
- Naber, K.G., Schito, G., Botto, H., Palou, J., and Mazzei, T. *Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.* (<http://dx.doi.org/10.1016/j.eururo.2008.05.010>) Eur Urol. 2008; 54: 1164–1178
- Nicolle, L.E., Bradley, S., Colgan, R. et al. *Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteruria in adults.* (<http://dx.doi.org/10.1086/427507>) Clin Infect Dis. 2005; 40: 643–654
- Gordon, K.A., Jones, R.N., and SENTRY Participant Groups (Europe, Latin America, North America). *Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America.* Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis. 2003; 45: 295–301



Johansen, T.E.B., Cek, M., Naber, K.G. et al. *Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics.* Data from the PEP and PEAP-studies. (<http://dx.doi.org/10.1016/j.ijantimicag.2006.05.005>) Int J Antimicrob Agents. 2006; 28: S91–S107

Wagenlehner, F.M.E., van Oostrum, E., Tenke, P. et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. (<http://dx.doi.org/10.1016/j.eururo.2012.06.003>) Eur Urol. 2013; 63: 521–527

Wagenlehner, F.M.E., Cek, M., Naber, K.G., Kiyota, H., and Bjerklund-Johansen, T.E. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. (<http://dx.doi.org/10.1007/s00345-011-0757-1>) World J Urol. 2012; 30: 59–67

Hooton, T.M., Roberts, P.L., Cox, M.E., and Stapleton, A.E. *Voided midstream urine culture and acute cystitis in premenopausal women.* (<http://dx.doi.org/10.1056/NEJMoa1302186>) N Engl J Med. 2013; 369: 1883–1891

Gleckman, R., Esposito, A., Crowley, M., and Natsios, G.A. *Reliability of a single urine culture in establishing diagnosis of asymptomatic bacteriuria in adult males.* J Clin Microbiol. 1979; 9: 596–597

Warren, J.W., Tenney, J.H., Hoopes, J.M., Muncie, H.L., and Anthony, W.C. *A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters.* J Infect Dis. 1982; 146: 719–723

Kunin, C.M. *Urinary Tract Infections: Detection, Prevention, and Management.* Lippincott Williams & Wilkins, Philadelphia, PA; 1997.

Alteri, C.J. and Mobley, H.L.T. *Quantitative profile of the uropathogenic Escherichia coli outer membrane proteome during growth in human urine.* (<http://dx.doi.org/10.1128/IAI.00076-06>) Infect Immun. 2007; 75: 2679–2688

Dobardzic, A.M. and Dobardzic, R. *Epidemiological features of complicated UTI in a district hospital of Kuwait.* Eur J Epidemiol. 1997; 13: 465–470

Hooton, T.M. *Recurrent urinary tract infection in women.* Int J Antimicrob Agents. 2001; 17: 259–268



Antibiotic resistance threats in the United States, 2013. *Centers for Disease Control and Prevention*, U.S. Department of Health and Human Services, Atlanta, GA; 2013

Elias, J., Schoen, C., Heinze, G. et al. *Nosocomial outbreak of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa associated with retrogradeurography.* (<http://dx.doi.org/10.1111/j.1469-0691.2009.03146.x>) Clin Microbiol Infect. 2010; 16: 1494–1500

Madigan M. 2005. *Brock Biology of Microorganisme*. Hlmn :753. London: PrenticeHall.

Prais D, Straussberg R, Avitzur Y, Nussinovitch M, Harel L, Amir J. *Bacterial susceptibility to oral antibiotics in community acquired urinary tract infection*. Archs Dis Child 2003;88:215-8.

Ladhani S, Gransden W. *Increasing antibiotikresistance among urinary tract isolates*. Archs Dis child 2003; 88:444-5.

San, NM. *Gambaran pola kuman dan sensitifitasnya terhadap antibiotik* [abstrak]. Medan: Fakultas Kedokteran Universitas Sumatera Utara,2011.

Samirah, Darwati, Windarwati, Hardjoeno. *Pola dan sensitivitas kuman di penderita infeksi saluran kemih*. Indones J Clin Path Med Lab 2006;12:110-3.

Taneja N, Chatterjee SS, Singh M, Singh S , Sharma M. *Indian pediatric urinary tract infections in a tertiary care center from North India*. J Med Res 2010;131:101-5.

Hellerstain S. *Recurrent urinary tract infection in children*. Pediatr Infect Dis 2006;1:271-81

Mirawati T, Karuniawati A, Ningsih I KA, Tjampakasari CR, Hutabarat T dkk. *Hasil uji resistensi bakteri terhadap berbagai antibiotik di laboratorium mikrobiologi klinik FK-UI*. Jakarta: Laboratorium Mikrobiologi Klinik FKUI;2004.

Zalmanovici Trestioreanu A, Green H, Paul M, Yaphe J, et al. .. (2010) *Antimicrobial agents for treating uncomplicated urinary tract infection in women*. Cochrane Database of Systemic Reviews, Issue 10. Art. No.: CD007182. DOI: 10.1002/14651858.CD007182.pub2.

Kahne D, Leimkuhler C, Lu W, Walsh C. *Glycopeptide and lipoglycopeptide antibiotics*. Chem Rev. 2005;105:425–48.



Reynolds PE. *Structure, biochemistry and mechanism of action of glycopeptide antibiotics.* Eur J Clin Microbiol Infect Dis. 1989;8:943–50.

Džidić S, Šušković J, Kos B. *Antibiotic resistance mechanisms in bacteria: Biochemical and genetic aspects.* Food Technol Biotechnol. 2008;46:11–21.

Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. *Emergence and resurgence of meticillin-resistant *Staphylococcus aureus* as a public-health threat.* Lancet. 2006;368:874–85.

Yoneyama H, Katsumata R. *Antibiotic resistance in bacteria and its future for novel antibiotic development.* Biosci Biotechnol Biochem. 2006;70:1060–75.

Johnston NJ, Mukhtar TA, Wright GD. *Streptogramin antibiotics: Mode of action and resistance.* Curr Drug Targets. 2002;3:335–44.

Wise R. *A review of the mechanisms of action and resistance of antimicrobial agents.* Can Respir J. 1999;6(Suppl A):20A–2A.

Lambert PA. *Bacterial resistance to antibiotics: Modified target sites.* Adv Drug Deliv Rev. 2005;57:1471–85.

Higgins PG, Fluit AC, Schmitz FJ. *Fluoroquinolones: Structure and target sites.* Curr Drug Targets. 2003;4:181–90.

Brooks GF, Butel JS, dan Morse SA. 1998. *Jawetz, Melnick, & Adelberg's Medical Microbiology, 21<sup>st</sup> ed*, Prentice Hall International Inc, , 145 – 176.  
Levy SB. 1998.

Moehario LH. 1986. *Aspek genetik resistensi kuman. Simposium Perkembangan Antibiotik pada Penanggulangan Infeksi dan Resistensi Kuman*, Jakarta.

Neu HC, Gootz TD. 2001. *Antimicrobial chemotherapy*. Medmicro.

Sande AS, Kapusnik-Uner JE, dan Mandell GL. 1990. *Antimicrobial Agents, General Considerations*. Dalam : Gilman AG, Rall TW, Nies AS, dan Taylor P (Eds), *Goodman and Gilman's The Pharmacological Basis of Therapeutics*, 8<sup>th</sup> ed., Pergamon Press, 1018 – 1046.

Ramanath KV, Shafiya SB. *Prescription pattern of antibiotic usage for urinary tract infection treated in a rural tertiary care hospital.* Indian Journal of Pharmacy Practice 2011; 4(2): 57-63.



- Khanfar HS, Bindyna KM, Senok AC, Botta GA. *Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings.* J Infect Dev Ctries 2009; 3(4): 295-299
- Kahuripan A, Andrajati R, Syafridani T. *Analisis pemberian antibiotik berdasarkan hasil uji sensitivitas terhadap pencapaian clinical outcome pasien infeksi ulkus diabetik di RSUD DR. H. Abdul Moeloek Lampung.* Majalah Ilmu Kefarmasian 2009; 6(2): 75-87.
- Bugg T. D. H. & Walsh C. T. (1992). *Intracellular steps of bacterial cell wall peptidoglycan biosynthesis: Enzymology, antibiotics, and antibiotic resistance.* Nat. Prod. Rep. 9:199-215.
- Holtje J. V. (1998). *Growth of the stress bearing and shape maintaining murein sacculus of Escherichia coli.* Microbiol. Mol. Biol. Rev. 62:181- 189.
- Park J. T. & Uehara T. (2008). *How bacteria consume their own exoskeleton (turnover and recycling of cell wall-peptidoglycan).* Microbiol. Mol. Biol. 72:211-227.
- Josephine H. R., Kumar I. & Pratt R. F. (2004). *The Perfect Pencillin? Inhibition of a bacterial DD-peptidase by peptidoglycan-mimetic beta-lactams.* J. Am. Chem. Soc. 126:81222-81223.
- Madigan M. T. & Martinko J. M. (2006). *Brock biology of microorganisms.* 11th edition. Pearson Prentice Hall Inc.
- Alborn W., Allen N. & Preston D. (1991). *Deptomycin disrupts membrane potential in growing Staphylococcus aureus.* Antimicrob. Agents Chemother. 31(7):1093-1099.
- Falagas M. E., Rafailidis P. I. & Matthaiou D. K. (2010). *Resistance to polymyxins: Mechanisms, frequency and treatment options.* Drug Resist. Update. 13:132-138
- Gale E., Cundliffe E., Reynolds P. E., Richmond M. H. & Waring M. J. (1981). *The molecular basis of antibiotic action.* 2nd Ed. John Wiley & Sons, New York. 670p.
- Chen C. R., Malik M., Snyder M. & Drlica K. (1996). *DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone – induced DNA cleavage.* J. Mol. Biol. 258:627-637.
- Douthwaite S. (1992). *Interaction of the antibiotics clindamycin and lincomycin with Escherichia coli 23S ribosomal RNA.* Nucleic Acids Res. 20:4717-4720.
- Katz L. & Ashley G. W. (2005). *Translation and protein synthesis: macrolides.* Chem. Rev. 105:499-528.



Vannuffel P. & Cocito C. (1996). *Mechanism of action of streptogramins and macrolides*. Drugs. 51(1):20-30.

Menninger J. R. & Otto D. P. (1982). *Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes*. Antimicrob. Agents Chemother. 21:811-818.

Patel G. & Bonomo R. A. (2011). *Status report on carbapenemases: challenges and prospects*. Expert Rev. Anti. Infect. Ther. 9:555-570.

Tenson T., Lovmar M. & Ehrenberg M. (2003). *The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome*. J. Mol. Biol. 330(5):1005- 1014.

Hong W., Zeng J. & Xie J. (2014). *Antibiotic drugs targeting bacterial RNAs*. Acta Pharm. Sin B. 4(4):258-265.

Chopra I. & Roberts M. (2001). *Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance*. Microbiol. Mol. Biol. Rev. 65(2):232-260.

Epe B. & Woolley P. (1984). *The binding of 6-demethylchlortetracycline to 70S, 50S and 30S ribosomal particles: A quantitative study by fluorescence anisotropy*. EMBO J. 3:121-126.

Wilson DN. 2014. *Ribosome-targeting antibiotics and mechanisms of bacterial resistance*. Nat Rev Microbiol 12:35–48.

Ramirez MS, Tolmasky ME. 2010. *Aminoglycoside modifying enzymes*. Drug Resist Updat 13:151–171.

Pagès JM, James CE, Winterhalter M. 2008. *The porin and the per- meating antibiotic: a selective diffusion barrier in Gram-negative bacteria*. Nat Rev Microbiol 6:893–903.

Nikaido H. 2003. *Molecular basis of bacterial outer membrane per-meability revisited*. Microbiol Mol Biol Rev 67:593–656.